These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1706439)

  • 41. Correlation of clinical stage, serum prostatic acid phosphatase and preoperative Gleason grade with final pathological stage in 275 patients with clinically localized adenocarcinoma of the prostate.
    Oesterling JE; Brendler CB; Epstein JI; Kimball AW; Walsh PC
    J Urol; 1987 Jul; 138(1):92-8. PubMed ID: 3599229
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Correlation between prostate specific antigen and histopathologic findings in ileum-obturator node dissection].
    Scorticati C; Montes de Oca L; Bencardino F; López M; Suárez P; Bernardo N; Rozanec J; Bellora O; Holst P; Coste Delvecchio F; Scorticati C
    Arch Esp Urol; 1997; 50(1):41-4. PubMed ID: 9182487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combining prostate specific antigen with cancer and gland volume to predict more reliably pathological stage: the influence of prostate specific antigen cancer density.
    Blackwell KL; Bostwick DG; Myers RP; Zincke H; Oesterling JE
    J Urol; 1994 Jun; 151(6):1565-70. PubMed ID: 7514689
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum prostate-specific antigen and the biologic progression of prostate cancer.
    Kabalin JN; McNeal JE; Johnstone IM; Stamey TA
    Urology; 1995 Jul; 46(1):65-70. PubMed ID: 7541589
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Histopathological characteristics of lymph node metastases predict cancer-specific survival in node-positive prostate cancer.
    Boormans JL; Wildhagen MF; Bangma CH; Verhagen PC; van Leenders GJ
    BJU Int; 2008 Dec; 102(11):1589-93. PubMed ID: 18710447
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Limitations of serum prostate specific antigen in predicting peripheral and transition zone cancer volumes as measured by correlation coefficients.
    Noldus J; Stamey TA
    J Urol; 1996 Jan; 155(1):232-7. PubMed ID: 7490842
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The role of prostate-specific antigen in the diagnosis and treatment of prostatic adenocarcinoma].
    Stamey TA
    Urologe A; 1990 Mar; 29(2):52-64. PubMed ID: 1691883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. External validation of the updated nomogram predicting lymph node invasion in patients with prostate cancer undergoing extended pelvic lymph node dissection.
    Gacci M; Schiavina R; Lanciotti M; Masieri L; Serni S; Vagnoni V; Abdollah F; Carini M; Martorana G; Montorsi F
    Urol Int; 2013; 90(3):277-82. PubMed ID: 23296120
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 50. DNA ploidy, serum prostate specific antigen, histological grade and immunohistochemistry as predictive parameters of lymph node metastases in T1-T3/M0 prostatic adenocarcinoma.
    Berner A; Waere H; Nesland JM; Paus E; Danielsen HE; Fosså SD
    Br J Urol; 1995 Jan; 75(1):26-32. PubMed ID: 7531589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Implications of prostate micrometastases in pelvic lymph nodes: an archival tissue study.
    Edelstein RA; Zietman AL; de las Morenas A; Krane RJ; Babayan RK; Dallow KC; Traish A; Moreland RB
    Urology; 1996 Mar; 47(3):370-5. PubMed ID: 8633404
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prospective analysis of prostate-specific markers in pelvic lymph nodes of patients with high-risk prostate cancer.
    Ferrari AC; Stone NN; Eyler JN; Gao M; Mandeli J; Unger P; Gallagher RE; Stock R
    J Natl Cancer Inst; 1997 Oct; 89(20):1498-504. PubMed ID: 9337346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
    Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
    J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer?
    Schumacher MC; Burkhard FC; Thalmann GN; Fleischmann A; Studer UE
    Eur Urol; 2006 Aug; 50(2):272-9. PubMed ID: 16632187
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of preoperative ProstaScint scans in the prediction of nodal disease.
    Ponsky LE; Cherullo EE; Starkey R; Nelson D; Neumann D; Zippe CD
    Prostate Cancer Prostatic Dis; 2002; 5(2):132-5. PubMed ID: 12497003
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database.
    Schiavina R; Bianchi L; Borghesi M; Briganti A; Brunocilla E; Carini M; Terrone C; Mottrie A; Dente D; Gacci M; Gontero P; Gurioli A; Imbimbo C; La Manna G; Marchioro G; Milanese G; Mirone V; Montorsi F; Morgia G; Munegato S; Novara G; Panarello D; Porreca A; Russo GI; Serni S; Simonato A; Urzì D; Verze P; Volpe A; Martorana G
    Int J Urol; 2016 Dec; 23(12):1000-1008. PubMed ID: 27620370
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic significance of antigenic heterogeneity, Gleason grade, and ploidy of lymph node metastases in patients with prostate cancer.
    Bazinet M; Hamdy SM; Bégin LR; Stephenson RA; Fair WR
    Prostate; 1992; 20(4):311-26. PubMed ID: 1376912
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prostate-specific antigen and external beam radiation therapy in prostate cancer.
    Zagars GK; Sherman NE; Babaian RJ
    Cancer; 1991 Jan; 67(2):412-20. PubMed ID: 1702349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of pelvic lymph node metastasis by the ratio of cathepsin B to stefin A in patients with prostate carcinoma.
    Sinha AA; Quast BJ; Wilson MJ; Fernandes ET; Reddy PK; Ewing SL; Gleason DF
    Cancer; 2002 Jun; 94(12):3141-9. PubMed ID: 12115346
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prognostic factors in lymph node-positive prostate cancer.
    Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
    Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.